Dr.ir. Jan Schrooten is co-founder and CEO of Antleron, a young R&D company on a mission to enable personalized manufacturing 4.0 in the domain of advanced therapies. The core concept of Antleron’s collaborative innovation is integrating 3D printing, bioreactor-based cell-production processes and digital process control & optimization into factories-of-the-future for cell & gene therapy, vaccine and tissue manufacturing. Previously Jan Schrooten was senior research manager at KU Leuven (Belgium), responsible for the long-term management and technology transfer of biomaterials and tissue engineering research. Trained as a materials engineer, with an engineering PhD in biomaterials and a postgraduate in business administration, he has 25+ years of research experience in biomaterials and tissue engineering.
The importance of adopting in silico methods has become obvious, and pharmaceutical leaders are looking for the most efficient ways to adopt this technology quickly while minimizing risk and uncertainty. In silico veterans, including executives from Amgen, CEO of startup company Antleron, technical leaders from Ansys, and an academic thought leader will discuss the importance of an ecosystem and their recommendations for the successful adoption of CM&S during this prestigious panel discussion chaired by Ansys CTO, Prith Banerjee.
Check out the incredible speaker line-up to see who will be joining Jan.
Download The Latest Agenda